Resources

Laboratório Edol’s artwork includes big pieces of text, but since implementing TVT they now have complete control over their documents.

DSN has a long-standing reputation as one of the biggest players in pre-media and understands the needs and concerns of brand owners. TVT is expected to save DSN 300 – 600 hours annually, or 7.5 to 15 weeks.

Since implementing TVT, Dr. Pfleger Arzneimittel has become more efficient and could significantly scale up their output.

Pharmathen is one of Europe's largest independent generic companies. What used to take 3 days to review is now accomplished in only 1 day with TVT. This has resulted in weeks of gained time and reduced stress.

Biomapas, a full service CRO, was experiencing challenges verifying multiple languages. With TVT they can easily compare 64 required languages and save a minimum of 1-2 days per piece.

Thinkinpress, a global provider of artwork management and artwork support for the pharmaceutical industry achieves 100% quality assurance and have doubled their productivity since implementing TVT.

Still proofreading manually? There are hidden dangers in doing so: 50% of product recalls are due to packaging errors. Learn why companies can't afford to have highly-qualified professionals manually proofreading material.

Featured in Pharmaceutical Manufacturing and Packing Sourcer: The proofreading process in the pharmaceutical industry is full of risks. Marc Chaillou explains how you can avoid these risks with automated proofreading.

Featured in European Biopharmaceutical Review: Automated content checking can compare and accurately pinpoint anomalies. The time taken to verify output can be cut by as much as 85%.

Featured in Innovations in Pharmaceutical Technology: Forward-thinking companies are treating the delay of IDMP as an opportunity to quantify the data preparation task ahead. Organisations will need help to complete the groundwork, but the priority is ensuring that the data is correct, complete and clean.

Featured in International Pharmaceutical Industry: The life sciences industry is in a state of flux for a number of reasons. This article explains the five biggest sources of disruption to pharmaceutical companies.

Featured in European Pharmaceutical Manufacturer: The UK’s separation from the EU could have implications for regulatory harmonisation, and increase administrative workloads at a time when responsible teams are already overstretched and experienced talent is hard to find. Dr. Jutta Hohenhörst explains the impact.

Featured in the Journal for Clinical Studies: Life sciences technology vendors and consultancies are busy promoting IDMP compliance solutions, which seems odd given that many details of the final requirements have yet to be published.

Featured on Pharmiweb.com: How will Brexit and other challenges to the status quo affect plans to raise life sciences standards across Europe and internationally? Ask Dr. Jutta Hohenhörst.

Featured on PharmExec.com: If pharmaceutical companies want to hold their own in the current climate, they must embrace, rather than resist, market change. Peter Muller provides five trends that threaten the status quo.

Featured in the Journal for Clinical Studies: Bringing a new drug to market costs millions, so it’s highly risky to leave product labelling and packaging to chance - especially when expensive professionals are devoting hours of their time to these repetitive manual processes.

Featured in International Pharmaceutical Industry: Growing complexity in life sciences is raising the risk of product mislabelling, potentially putting lives in danger and leaving companies open to hefty fines and delays in product availability, warns Marc Chaillou.

Featured in International Pharmaceutical Industry: Regulators’ appetite for transparency and adherence to standards is increasing. Their goals are to protect and inform consumers.

Featured in Pharmaceutical Manufacturing and Packaging Sourcer: The line between pharma and food is blurring with the surge in nutraceuticals, and regulators are now playing catch-up. For organisations lacking a life sciences heritage, the stringent rules will affect all kinds of internal documentation processes.

Featured in Pharma Exec: The pharma and food industries are becoming closer and closer, presenting a great opportunity for life sciences firms to diversify.

Featured in Inside Food: In May, the FDA announced new guidance on food labelling, mirroring a move in Europe to improve transparency and safety for consumers. The aim is to provide more detailed health and nutrition information, but will how much will it add to the workload for manufacturers?

Featured on Pharmiweb: It’s hard enough for pharma companies to find and keep top regulatory talent in the current climate. To reduce this risk, firms need to automate more of their routine processes.

Featured in International Pharmaceutical Industry: The life sciences industry is drowning in a sea of new regulations and directives. As well as being immensely demanding from a risk management perspective, the associated administration is detracting from core activities. 

Featured in Pharma Exec: Soaring regulatory requirements are tying up RA and QA talent: This is an inefficient use of costly resources, and it undermines job satisfaction by failing to channel professionals’ intelligence.